Brachytherapy decreases risk of prostate cancer five-year recurrence
the ONA take:
According to results presented at the 3rd ESTRO Forum in Barcelona, Spain, researchers have found that men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later than those who received dose-escalated external beam radiotherapy.
For the study, researchers enrolled 398 men with localized prostate cancer who were at high risk for treatment failure. All patients initially received 8 months of androgen deprivation therapy followed by external beam radiotherapy to the prostate and lymph nodes.
Then, half of the patients received low-dose-rate prostate brachytherapy while the other half received additional dose-escalated external beam radiation therapy.
"This study illustrates very nicely how the best results can be obtained by combining various treatment options instead of trying to get the most out of one single modality. Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumors when combined with other techniques - in this case, androgen deprivation therapy and external bean radiation therapy," said Philip Poortmans, MD, PhD, President of ESTRO.
Men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|